RXRX Recursion Pharmaceuticals Inc
Price (delayed)
$5.29
Market cap
$2.13B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$1.64B
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients
Highlights
RXRX's equity has soared by 123% year-on-year and by 97% since the previous quarter
RXRX's revenue is up by 32% year-on-year but it is down by 10% since the previous quarter
The debt has surged by 114% year-on-year and by 20% since the previous quarter
Recursion Pharmaceuticals's gross profit has decreased by 41% from the previous quarter
Key stats
What are the main financial stats of RXRX
Market
Valuations
Earnings
Shares outstanding
401.99M
Market cap
$2.13B
Enterprise value
$1.64B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.47
Price to sales (P/S)
24.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.83
Revenue
$58.84M
Gross profit
$13.6M
Operating income
-$479M
Net income
-$463.66M
EBIT
-$464.79M
EBITDA
-$411.68M
Free cash flow
-$372.87M
Per share
Balance sheet
Liquidity
EPS
-$1.69
EPS diluted
-$1.69
Free cash flow per share
-$1.36
Book value per share
$3.61
Revenue per share
$0.21
TBVPS
$3.52
Total assets
$1.45B
Total liabilities
$413.82M
Debt
$108.49M
Equity
$1.03B
Working capital
$526.8M
Debt to equity
0.1
Current ratio
3.81
Quick ratio
3.45
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-699.7%
Gross margin
23.1%
Net margin
-788%
Operating margin
-814.1%
Return on assets
-52.9%
Return on equity
-72.9%
Return on invested capital
-220.3%
Return on capital employed
-36.9%
Return on sales
-789.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RXRX stock price
How has the Recursion Pharmaceuticals stock price performed over time
Intraday
3.83%
1 week
-14.26%
1 month
-29.56%
1 year
-39.68%
YTD
-21.75%
QTD
0%
Financial performance
How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$58.84M
Gross profit
$13.6M
Operating income
-$479M
Net income
-$463.66M
Gross margin
23.1%
Net margin
-788%
Recursion Pharmaceuticals's gross profit has decreased by 41% from the previous quarter
Recursion Pharmaceuticals's net income has decreased by 41% YoY and by 23% from the previous quarter
Recursion Pharmaceuticals's operating income has decreased by 37% YoY and by 22% QoQ
The net margin has declined by 36% since the previous quarter and by 7% year-on-year
Growth
What is Recursion Pharmaceuticals's growth rate over time
Valuation
What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.47
P/S
24.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.83
The company's EPS fell by 9% QoQ and by 7% YoY
RXRX's equity has soared by 123% year-on-year and by 97% since the previous quarter
RXRX's price to book (P/B) is 61% lower than its last 4 quarters average of 3.6
RXRX's price to sales (P/S) is 36% lower than its last 4 quarters average of 36.9
RXRX's revenue is up by 32% year-on-year but it is down by 10% since the previous quarter
Efficiency
How efficient is Recursion Pharmaceuticals business performance
The company's return on sales fell by 34% QoQ and by 6% YoY
RXRX's ROIC is up by 27% YoY
Recursion Pharmaceuticals's return on assets has increased by 5% QoQ but it has decreased by 3.9% YoY
Recursion Pharmaceuticals's return on equity has increased by 4.8% QoQ
Dividends
What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RXRX.
Financial health
How did Recursion Pharmaceuticals financials performed over time
The total assets has surged by 122% year-on-year and by 99% since the previous quarter
The total liabilities has soared by 117% YoY and by 105% from the previous quarter
The debt is 90% smaller than the equity
RXRX's equity has soared by 123% year-on-year and by 97% since the previous quarter
The debt has surged by 114% year-on-year and by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.